IP Library Granted Patent US 7,323,490
Granted Patent B2
US 7,323,490 · App. 10/848,584 · Granted Jan 29, 2008

Pyrrole compounds and uses thereof

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,323,490
App. No.
10/848,584
Granted
Jan 29, 2008
Kind
B2
Abstract

The invention provides pyrrole-containing compounds and methods of use thereof. Kits and pharmaceutical compositions comprising the pyrrole compounds of the invention are also provided. The compounds and compositions disclosed herein are preferably used in the treatment of neurodegenerative diseases, cardiovascular diseases, proliferative diseases, and visual disorders. In particular, methods and compositions for the treatment of stroke are disclosed herein.

Claims (18)

1. A pyrrole compound having the formula:

or a diastereomer, enantiomer, or pharmaceutically acceptable salt thereof.

2. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable excipient.

3. A method of treating stroke comprising administering to a subject in need thereof an effective amount of a compound of claim 1 .

4. The method of claim 3 , wherein the method is for treating post stroke trauma.

5. A method for treating trauma associated with stroke comprising administering to a subject in need thereof an effective amount of a compound of claim 1 after said stroke.

6. The method of claim 5 , wherein said compound is administered within the first 48 hours of the onset of symptoms.

7. The method of claim 5 , wherein said compound is administered within the first 6 hours of the onset of symptoms.

8. The method of claim 5 , wherein said compound is administered within the first 3 hours of the onset of symptoms.

9. The method of claim 5 , wherein said compound is administered via intravenous injection, bolus injection, a pill, a capsule, transdermal patch or buccal delivery.

10. A kit comprising a carrier, package or container, wherein said carrier, package or container(s) comprises a compound of formula:

or a diastereomer, enantiomer, or pharmaceutically acceptable salt thereof, and wherein said kit optionally comprises one or more additional containers, each said container comprising one or more reagents or materials.

11. The kit of claim 10 , wherein said containers are selected from bottles, vials, syringes and test tubes.

12. The kit of claim 10 , wherein said materials are selected from buffers, diluents, filters, needles, syringes, carrier, package, container, vial and instructions for use.

13. The compound of claim 1 , wherein the compound is

14. The compound of claim 1 , wherein the compound is a diastereomer of the compound of formula

15. The compound of claim 1 , wherein the compound is an enantiomer of the compound of formula

16. The compound of claim 1 , wherein the compound is a pharmaceutically acceptable salt of the compound of formula

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded Mar 7, 2008
From: HORIZON TECHNOLOGY FUNDING COMPANY LLC
To: AMBIT BIOSCIENCES CORPORATION
Reel/Frame 020619/0693 →
SECURITY AGREEMENT Recorded Oct 17, 2005
From: AMBIT BIOSCIENCES CORPORATION
To: HORIZON TECHNOLOGY FUNDING COMPANY LLC
Reel/Frame 017261/0630 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 2, 2004
From: LOCKHART, DAVID J.; PATEL, HITESH K.; MILANOV, ZDRAVKO; MEHTA, SHAMAL ANIL; ZARRINKAR, PATRICK P.; BIGGS, III, WILLIAM H.; CICERI, PIETRO; FABIAN, MILES A.; TREIBER, DANIEL K.
To: AMBIT BIOSCIENCES CORPORATION
Reel/Frame 015648/0421 →